

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

X Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m/p.m.

Dated: April 3, 2002

Name of Person Certifying: _____
Printed Name: Nancy Hine

Nancy Hine



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jones et al.

Assignee: Genencor International, Inc.

Filing Date: November 9, 1999

Examiner: Patterson, C.

Serial No.: 09/436,513

Group Art Unit: 1652

Title: Chemically Modified Mutant Serine Hydrolases Show Improved Catalytic Activity And Chiral Selectivity

TECH CENTER 1600/2900

APR 19 2002

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE (37 C.F.R. § 1.111)

Dear Sir:

Responsive to the Office Action mailed October 4, 2001 ("Office Action" or "Paper No. 14"), Applicants request a three-month extension of time and authorize withdrawal of the appropriate fee from the deposit account identified in the accompanying response transmittal. Applicants thank Examiner Patterson for the courtesy extended in a telephonic interview conducted March 18, 2002. Applicants respectfully request reconsideration of the above-identified application in view of the following remarks.

REMARKS

Objections to the Specification

The following objections to the specification have been raised by the Examiner¹:

In Figure 3 the recitation of "MOM" is not understood and in Figure 4 the recitation of "Bn" is not understood. Applicant states that "MOM" stands for "Methoxymethoxy" and that this is described on page 18, line 30 and page 26, line 20. In the first case only the abbreviation "MOM" is recited without a definition" and in the second case "methoxymethoxy" is recited without the

¹ The Office Action characterized these objections as a 112, first paragraph written description rejection of claims 1-11, 13, 51-57, 59 and 61-62. See Office Action at pages 2-3. Applicants believe that their responses to the objections noted by the Examiner address any potential 112, first paragraph written description rejections related to the specific objections raised in the Office Action.